Dieter Köberle

Docetaxel, Cisplatin, and Fluorouracil; Docetaxel and Cisplatin; and Epirubicin, Cisplatin, and Fluorouracil As Systemic Treatment for Advanced Gastric Carcinoma: A Randomized Phase II Trial of the Swiss Group for Clinical Cancer Research

Arnaud Roth, Nicola Fazio, Roger Stupp et al. · Journal of Clinical Oncology · 2007 · 244 citations · Full text

Clinical benefit of fulvestrant in postmenopausal women with advanced breast cancer and primary or acquired resistance to aromatase inhibitors: final results of phase II Swiss Group for Clinical Cancer Research Trial (SAKK 21/00)

Lucien Perey, Robert Paridaens, Hanne Hawle et al. · Annals of Oncology · 2006 · 134 citations · Full text

Breast Oncology, Sakk 21/00, Medicine +13

Gender-specific elimination of continuous-infusional 5-fluorouracil in patients with gastrointestinal malignancies: results from a prospective population pharmacokinetic study

F Mueller, Barbara Büchel, Dieter Köberle et al. · Cancer Chemotherapy and Pharmacology · 2012 · 94 citations · Full text

Oncology, Gastrointestinal Oncology, Medicine +7

Multicenter phase II trial of preoperative induction chemotherapy followed by chemoradiation with docetaxel and cisplatin for locally advanced esophageal carcinoma (SAKK 75/02)

Thomas Ruhstaller, L. Widmer, Jan C. Schuller et al. · Annals of Oncology · 2009 · 72 citations · Full text

Sakk 75/02, Preoperative Induction Chemotherapy, Esophageal Cancer +7

Anastrozole (‘Arimidex’) versus tamoxifen as first-line therapy in postmenopausal women with advanced breast cancer: Results of the double-blind cross-over SAKK trial 21/95 - a sub-study of the TARGET (Tamoxifen or ‘Arimidex’ Randomized Group Efficacy and Tolerability) trial

Beat Thürlimann, Dagmar Hess, Dieter Köberle et al. · Breast Cancer Research and Treatment · 2004 · 71 citations

First-line Therapy, Breast Oncology, ‘ Arimidex ’ +13